Bristol-Myers Squibb Is A Good Pick

My last article about Bristol-Myers Squibb Company (NYSE: BMY ) was published in December 2024, and back then, I called the stock a "Buy" once again. In the meantime, the stock has declined about 14% compared to December 2024, and lost close to 25% in the lastMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraint ...